Tacrolimus dose requirement based on the CYP3A5 genotype in renal transplant patients

Tacrolimus (FK506) and cyclosporine A (CsA) are widely used to protect graft function after renal transplantation. The aim of the present study is to determine whether the single nucleotide polymorphism of CYP3A5 is a predictive index of FK506 dose requirement, and also the selection yardstick of FK...

Ausführliche Beschreibung

Gespeichert in:
Bibliographische Detailangaben
Veröffentlicht in:Oncotarget 2017-10, Vol.8 (46), p.81285-81294
Hauptverfasser: Qu, Lihui, Lu, Yingying, Ying, Meike, Li, Bingjue, Weng, Chunhua, Xie, Zhoutao, Liang, Ludan, Lin, Chuan, Yang, Xian, Feng, Shi, Wang, Yucheng, Shen, Xiujin, Zhou, Qin, Chen, Ying, Chen, Zhimin, Wu, Jianyong, Lin, Weiqiang, Shen, Yi, Qin, Jing, Xu, Hang, Xu, Feng, Wang, Junwen, Chen, Jianghua, Jiang, Hong, Huang, Hongfeng
Format: Artikel
Sprache:eng
Schlagworte:
Online-Zugang:Volltext
Tags: Tag hinzufügen
Keine Tags, Fügen Sie den ersten Tag hinzu!
Beschreibung
Zusammenfassung:Tacrolimus (FK506) and cyclosporine A (CsA) are widely used to protect graft function after renal transplantation. The aim of the present study is to determine whether the single nucleotide polymorphism of CYP3A5 is a predictive index of FK506 dose requirement, and also the selection yardstick of FK506 or CsA treatment.We tested archival peripheral blood of 218 kidney recipients for CYP3A5 genotyping with PCR-SSP. Meanwhile, the dose of FK506 and CsA was recorded, blood concentration of the drugs was measured, and graft outcome was monitored.These results indicate that CYP3A5*AA/AG carriers need higher FK506 dose than CYP3A5*GG homozygote to achieve the target blood concentration. For CYP3A5*GG carriers, taking FK506 or CsA are both advisable. CYP3A5*AA/AG carriers preferred to CsA treatment depending on the graft outcomes and drug costs. CYP3A5 genotyping is a new approach to detecting FK506 dose requirement and a predictive index for the FK506 or CsA treatment selection in kidney recipients.
ISSN:1949-2553
1949-2553
DOI:10.18632/oncotarget.18150